Navigation Links
K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus
Date:6/17/2011

All statements that address expectations or projections about the future, including without limitation, statements about product development, product launches, regulatory approvals, governmental and regulatory actions and proceedings, market position, acquisitions, sale of assets, revenues, expenditures, resumption of manufacturing and distribution of products and the impact of the recall and suspension of shipments on revenues, and other financial results, are forward-looking statements.

All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the PSLRA's "safe harbor" provisions, the Company provides the following cautionary statements identifying important economic, competitive, political, regulatory and technological factors, among others, that could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following:

(1) the Company's ability to continue as a going concern;

(2) completion of the transactions contemplated by the definitive asset purchase agreement for the sale of the Company's generic products business and Nesher subsidiary and compliance by the Company and the buyer with their respective related contractual obligations;  

(3) the impact of competitive, commercial, payor, governmental (including Medicaid program), physician, patient, public or political responses and reactions, and responses and reactions by medical professional associations and advocacy groups, to the Company's sales, marketing, product pricing, product access and strategic efforts with respect to Makena™, and its other products, including introduction or potential introduction of generic or competing products, or competition from unapproved therapies or compounded drugs, against p
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Par Pharmaceutical Reports Second Quarter 2008 Results
3. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
4. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
5. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
6. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
11. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... September 17, 2014 Terracon Corporation has ... its TerraPure tank . This addition to the ... from FDA-compliant linear polyethylene and available in 125 or ... and ships in two weeks or less. , The ... benefits found in Terracon’s existing TerraPure tank line – ...
(Date:9/17/2014)... SOUTH SAN FRANCISCO, Calif. , Sept. 17, 2014 ... VCYT ), a molecular diagnostics company pioneering the field ... M. Hall to chief operating officer. Mr. ... to spearhead the company,s commercial entry into endocrinology. Since ... service operations, as well as managed care and billing ...
(Date:9/17/2014)... Scotland , September 17, 2014 /PRNewswire/ ... new mode of action from a truly ... decade  MGB Biopharma, a biopharmaceutical ... anti-infectives, announces today that it has secured ... its lead antibacterial, MGB-BP-3, against a range ...
(Date:9/16/2014)... 2014 This report analyzes the worldwide markets for ... Hardware, and Biocontent. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... of World. Annual estimates and forecasts are provided for the ... provided for these markets. Market data and analytics are derived ...
Breaking Biology Technology:Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23
... 13 Nile Therapeutics, Inc.,(Nasdaq: NLTX ), today ... present at the Rodman & Renshaw 5th Annual Global ... at Le Meridian Beach,Plaza Hotel in Monte Carlo, Monaco. ... the status of Nile,s current clinical development,programs., The ...
... Foamix Offers New Intravaginal Foam Technology with Improved Usability & ... ... Israel, May 13 Despite the high incidence,of women,s health conditions ... and ovules, a recent survey,found that an alarming majority of women ...
... with CelVida Yields First Milestone, NEW YORK, May ... pioneering the pre-disease collection, processing and long-term,storage of adult ... a,site has been secured for a new stem cell ... Robin Smith, MD MBA, NeoStem,s Chairman and Chief ...
Cached Biology Technology:Nile Therapeutics to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference 272% of Women Are Dissatisfied With Their Current Treatment of Vaginal Infection, Survey Finds 2NeoStem to Expand Stem Cell Collection Center Network to Florida 2NeoStem to Expand Stem Cell Collection Center Network to Florida 3
(Date:9/17/2014)... has developed, very cleverly, some lessons on how to ... said Joseph Shaw, director of the Optical Technology Center ... structures at the nanoscale, we,ll discover them." , Some ... August during a conference called "The Nature of Light: ... of the University of Arizona College of Optical Sciences. ...
(Date:9/17/2014)... at IMIM (Hospital del Mar Medical Research Institute) and ... published a study in eLife showing that ... the evolution of new proteins, some of which could ... produce proteins from the instructions found in an RNA ... RNA containing information for the synthesis of proteins, meaning ...
(Date:9/17/2014)... Mutations in the human retinoblastoma protein gene are a ... scientists have turned to fruit fly eyes to unlock ... In a paper featured on the cover of the ... , Michigan State University researchers provide the first detailed ... present in the human cancer gene, said Irina Pushel, ...
Breaking Biology News(10 mins):Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3Parts of genome without a known function may play a key role in the birth of new proteins 2Abnormal properties of cancer protein revealed in fly eyes 2
... A child,s chances of developing allergies or wheezing is related ... the womb, according to scientists from the University of Southampton. ... Council (MRC) and the British Lung Foundation, and undertaken at ... early pregnancy but falter later in pregnancy are likely to ...
... apply natural make-up to their feathers to stand out and ... from the Estacin Biolgica de Doňana in Seville, Spain, and ... transfer the color pigments (carotenoids) from the secretions of their ... is found in the majority of birds and is situated ...
... Pacific Data Designs) today announced that David Herron has ... executive officer.  In addition, David has been named to ... well equipped to lead this company into the next ... relationships and operational leadership are fundamentally important to ClinOps ...
Cached Biology News:Allergies and wheezing illnesses in childhood may be determined in the womb 2Beauty from the bottom up 2ClinOps Announces Appointment of New President and CEO 2
See product name for description....
2'-Fluorine-CTP (2'-F-CTP) is readily incorporated into transcripts by T7 and SP6 R&DNA™ Polymerase and is available separately....
Rat CINC-2 alpha/beta Affinity Purified Polyclonal Ab...
Human Contactin-2/TAG1 Affinity Purified Polyclonal Ab...
Biology Products: